Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Breakout Ventures
BioCentury | Aug 30, 2024
Finance
Finance Report: RA, Forbion back immunology play Navigator to develop bispecific
Plus: Series A for oncology play Noetik; China-based DualityBio files for Hong Kong IPO
BioCentury | Aug 19, 2023
Regulation
Aug. 18 Quick Takes: FDA approvals for Regeneron, Neurocrine
Plus: Priority review for full approval of Calliditas’ Tarpeyo and updates from Astellas-Iveric, Merck, Arch newco TFC
BioCentury | Jul 26, 2023
Finance
July 25 Quick Takes: Biogen cutting 1,000 jobs
Plus: Stoke falls on Dravet update and updates from Astellas-PeptiDream, Kiniksa and A-Alpha
BioCentury | Dec 20, 2022
Regulation
Dec. 20 Quick Takes: Verona lining up COPD submission after second Phase III readout
Plus: F-star takeout remains in CFIUS limbo and updates from Seagen, Astellas, Merck, Catalyst, Eisai and more
BioCentury | Apr 15, 2022
Product Development
April 14 Quick Takes: Evelo stalls early eczema program
Plus Ji Xing licenses to presbyopia therapies from Lenz, and updates from Surf Bio, UsAgainstAlzheimer and YouthBio
BioCentury | Dec 11, 2021
Product Development
Dec. 10 Quick Takes: UCB’s rozanolixizumab meets in Phase III
Plus: Vifor-Angion product misses and updates from Arvinas-Pfizer, Canbridge, Totus and more
BioCentury | Nov 3, 2021
Emerging Company Profile
Parthenon: Bringing down immune exclusion in cancer
Northpond and Pfizer, Taiho VC affiliates back $65M series A for newco exploring largely uncharted area of tumor immunotherapy biology
BioCentury | Jun 1, 2018
Finance
Bacterial brain
Why Sequoia is backing Cortexyme’s Alzheimer’s hypothesis by leading $76M round
Items per page:
1 - 10 of 12